Physician profile
Noah H Greene
NPI 1578788857
$6,092.88
in general payments reported to CMS, 2019-2025
33 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $578 · 2021: $886 · 2022: $708 · 2023: $775 · 2024: $1,099 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.67 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,623.63 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $775.43 | 2019-2024 | Xarelto |
| Pfizer INC. | $712.06 | 2019-2025 | |
| Amgen INC. | $345.85 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $305.74 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $264.24 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.61 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $251.81 | 2021-2025 | Farxiga, Brilinta, Lokelma |
| Merck Sharp & Dohme LLC | $127.87 | 2024-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $124.49 | 2019-2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $116.69 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $115.92 | 2019-2023 | |
| Amarin Pharma, INC. | $113.87 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.10 | 2019-2024 | Jardiance |
| Scpharmaceuticals INC. | $95.60 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $93.87 | 2020-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $71.13 | 2023-2024 | Inpefa |
| Baxter Healthcare | $67.08 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $66.78 | 2022 | |
| Abbott Laboratories | $48.49 | 2024 | Jot Dx |
| Lilly USA, LLC | $43.89 | 2025 | Zepbound, Mounjaro |
| Vifor Pharma, INC. | $43.28 | 2022 | |
| Arbor Pharmaceuticals, INC. | $42.68 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $42.64 | 2024 | Arcalyst |
| Cvrx, INC. | $41.59 | 2022 | |
| Jazz Pharmaceuticals INC. | $36.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.97 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.84 | 2024 | Onpattro |
| Medtronic Vascular, INC. | $24.46 | 2019 | |
| Cardiva Medical, INC. | $24.45 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Atricure, INC. | $19.84 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.33 | 2021 | |
| Bardy Diagnostics, INC. | $9.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.